Study says heart valve cuts deaths

Los Angeles Times - - Business -

Ed­wards Life­sciences Corp.’s Sapien heart valve may be­come the first life­sav­ing treat­ment in the U.S. for frail, el­derly pa­tients with dis­eased valves af­ter a study found it slashed deaths in those with few med­i­cal op­tions.

Ed­wards rose $7.89, or 13%, to $67.59 in the biggest sin­gle-day in­crease since July 2002. The Irvine firm’s shares have dou­bled in the last year as in­vestors an­tic­i­pated the study re­sults.

Ed­wards will use this re­search and tests in health­ier pa­tients to seek FDA ap­proval of the $30,000 valve next year.

If Sapien is safer and works as well as al­ter­na­tives in a broader group of pa­tients, Ed­wards may dou­ble sales to $2.8 bil­lion in five years, an­a­lysts sur­veyed by Bloomberg pro­jected.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.